Research Article

Relationship between Serum Osteocalcin and Carotid Atherosclerosis in Middle-Aged Men in China: A Cross-Sectional Study

Hui Deng,1 Hao Lu,1 Yang Dai,1 Lingling Li,1 Juan Cao,1 and Dalong Zhu2

1Department of Geriatrics, Drum Tower Clinical Medical College of Nanjing Medical University, China
2Department of Endocrinology, Drum Tower Clinical Medical College of Nanjing Medical University, China

Correspondence should be addressed to Dalong Zhu; zhudalong@nju.edu.cn

Received 4 February 2018; Revised 25 May 2018; Accepted 4 June 2018; Published 14 August 2018

Background and Purpose. Numerous investigations found that there exists a close relationship between serum osteocalcin and incurrence of atherosclerosis, but studies investigating the effect of serum osteocalcin on carotid atherosclerosis are very limited. Our study is aimed at investigating the role of osteocalcin in carotid atherosclerosis in middle-aged men in China.

Methods. A total of 335 male middle-aged participants (40-60, 52.4 ± 3.87 years averagely) were enrolled from the institute. The carotid intima-media thicknesses (CIMT) of each subject were measured. All subjects were included either in the carotid atherosclerosis (AS) group or the control group according to the CAS diagnosis criteria. Serum osteocalcin and other markers of each patient were assessed following standard laboratory tests protocol.

Results. 135 subjects were included in AS group, and 199 subjects were included in control group. The average osteocalcin level in AS group was 18.71 ± 6.20 ng/ml and was significantly different from that in control group, which was 20.38 ± 7.19 ng/ml (p=0.039). Logistic regression analysis revealed that OCN (standardized 𝛽=-0.024, p=0.013) and FINS (standardized 𝛽=-0.065, p=0.010) were independently and inversely associated with the carotid atherosclerosis, while FPG (standardized 𝛽=0.538, p=0.006) was independently and positively associated with the carotid atherosclerosis.

Conclusion. Our study suggests that OCN is independently related to carotid atherosclerosis in middle-aged male individuals.

1. Introduction

Atherosclerosis-induced cardiovascular events and cerebrovascular events cause death in almost 50% of cases in developed countries [1]. Of these fatal cases, 20% are related to carotid artery [2]. Patients with concomitant carotid atherosclerotic disease and coronary artery disease are more likely to have widespread atherosclerosis and are related to higher risk of recurrent symptoms and complications [3]. Several risk factors of carotid atherosclerotic disease, including smoking, age, hypertension, and abnormal levels of triglyceride and lipoprotein cholesterol, have been identified [4]. Notably, aggregating evidence demonstrated that the diabetes mellitus is an predicator of atherosclerosis [5].

Recently an increasing number of investigations found that bone metabolism could be related to carotid atherosclerosis. Carotid intima-media thickness (CIMT), known as a significant factor to increase the risk of myocardial infarction and ischemic stroke [6], was also reported to be closely related to lumbar spine BMD in postmenopausal women [7]. Atherogenic stimuli not only induce the transformation of smooth cells into osteoblast-like cells and acceleration of vascular calcification, but also prompt the release of bone formation markers and osteoclast differentiation and activation [8].

Osteocalcin (OCN), for example, a bone formation marker which is produced by osteoblastic cells and derived from procollagen metabolism, is a specific and sensitive parameter of bone remodeling involved in bone mineralization and calcium homeostasis [9]. OCN is reported to participate in the regulation of the adipose-related gene expression and influence the glucose tolerance, fat consumption, and insulin resistance [10]. Previous studies also found that bone remodeling could be regulated by adipose tissues through the...
effects of leptin on osteoblasts [11], and therefore a feedback loop with bone-regulated energy metabolism, and that bone in skeleton is indicated to be an endocrine organ.

Previously, the level of serum OCN was found to be closely related to the participants who had self-reported cardiovascular disease in middle and elderly aged Chinese [12]. Similarly, OCN is also found to be a critical determinant of coronary atherosclerotic severity in Chinese male participants [13]. On this basis, it is reasonable to deduce that serum OCN is a potential candidate for detecting the risk of carotid atherosclerosis and the abnormal glucose metabolism. In our study, to address this issue, we collected anthropometric parameters, serum OCN level, blood glucose, and lipid profile in a total of 355 middle age (40-60 years) men who were divided into AS group and control group according to the measurement of carotid intima-media thicknesses (CIMT), and their association with carotid atherosclerosis was analyzed.

2. Materials and Methods

2.1. Study Design and Study Objects. Between January 2014 and December 2016, male patients aged between 40 and 60 years who underwent routine medical health examination in Nanjing Drum Tower Hospital were screened and selected for our study. Our study was approved by the ethics committee of the institute and the informed consent was taken from all the patients. The physical characteristics of each patient including age, BMI, and waistline were recorded. Their history of alcohol consumption, current cigarette smoking, hypertensive disease, diabetes mellitus, bone fracture, and operations was recorded. Active smokers were defined as smoking more than 10 cigarettes per day. Smoking cases was recorded. Their history of alcohol consumption, current cigarette smoking, and current alcohol consumption, including age, BMI, and waistline were recorded. Their association with carotid atherosclerosis was analyzed.

2.2. Biochemical Analysis. After overnight fasting for a minimum of 12 hours, the blood samples were collected from each subject in the morning local time and transferred to serum separation tubes. After centrifugation, sera were obtained and were used for determining serum level of OCN. Specifically, hundreds of tests were uniformly conducted in the laboratory of the institute utilizing a computer automatically controlled analyzer for quantitively testing the OCN with reagent kit, and the whole procedures were strictly conducted by the same group of technicians according to the manufacturer’s manuals. On the other hand, liver and renal function markers, serum calcium, phosphorus, and alkaline phosphatase levels were also detected. The above test results regarding AS group and control group were further compared and analyzed.

2.3. Statistical Analysis. All data were expressed as means ± standard deviation (SD) or standard error (SE). All statistical analyses were performed using the SPSS 19.0 program, and significance level of p < 0.05 was used for all comparisons. Comparisons of OCN level and other serum metabolic markers compared between AS group and control group were assessed by the nonparametric Mann–Whitney U test. The correlation between significantly different markers and AS risk was analyzed by Spearman tests and logistic regression.

3. Results

3.1. The Characteristics of Study Population. OCN was non-normally distributed. The median of OCN was 17.87 (95% CI: 17.66 to 19.76) in AS group and 18.98 (95% CI: 19.38 to 21.39) in control group and was found to be significantly less in AS group than that in control group (18.71 ± 6.20 versus 20.38 ± 7.19, p=0.039). The mean data and standard deviation could be seen in Table 3.

The demographic and clinical characteristics of each subject in AS group and control group are presented in Table 1. The age, SBP and DBP, and BMI were compared, and no significant differences were found between two groups. There was also no significant difference found in the prevalence of smokers, hypertension, and smoking cases between AS group and control group (as shown in Table 2). Similarly, there was no significant difference between AS groups and control groups, regarding renal function markers (e.g., BUN, creatinine), some lipid markers (e.g., triglyceride, total cholesterol, and LDL-C), and other markers such as calcium and phosphorus. However, the FPG in AS group was found to be significantly higher than that in control group (5.81 ± 1.52 versus 5.32 ± 0.98, p=0.004), and the HbA1c was also found to be significantly higher in the AS group than control group (5.88 ± 0.88 versus 5.63 ± 0.67, p=0.008), indicating an impaired glucose tolerance. Moreover, the HDL-C was found to be significantly higher in control group than in AS group, implying a better inhibition to oxidation, coagulation, and platelet aggregation in nonatherosclerotic individuals [16].

3.2. Association of OCN with Other Metabolic Markers in AS Group and Control Group. The association between OCN and glucose metabolic markers were analyzed. In AS group, Spearman’s correlation analysis demonstrated a negative correlation between OCN and FPG (r = -0.389, p < 0.001),
Table 1: Demographic and clinical characteristics of patients.

| Markers          | AS group (Means ± SD) | Control group (Means ± SD) | Total (Means ± SD) | p value* |
|------------------|-----------------------|----------------------------|--------------------|----------|
| Number           | 136                   | 199                        | 335                |          |
| Age, years       | 52.45 ± 3.09          | 52.32 ± 4.80               | 52.4 ± 3.87        | 0.546    |
| OCN              | 18.71 ± 6.20          | 20.38 ± 7.19               | 19.71 ± 6.85       | 0.039    |
| SBP, mmHg        | 125.22 ± 15.23        | 123.24 ± 13.98             | 124.04 ± 14.53     | 0.332    |
| DBP, mmHg        | 80.39 ± 10.25         | 80.34 ± 9.59               | 80.36 ± 9.85       | 0.755    |
| BMI, kg/m²       | 25.41 ± 2.84          | 25.77 ± 2.85               | 25.62 ± 2.85       | 0.438    |
| FPG, mm/dl       | 5.81 ± 1.52           | 5.32 ± 0.98                | 5.52 ± 1.25        | 0.004    |
| PBG, mm/dl       | 7.47 ± 3.40           | 6.85 ± 2.41                | 7.10 ± 2.86        | 0.259    |
| HbA1c, %         | 5.88 ± 0.88           | 5.63 ± 0.67                | 5.73 ± 0.77        | 0.008    |
| FINS             | 10.05 ± 5.41          | 11.56 ± 6.89               | 10.94 ± 6.36       | 0.076    |
| Calcium, mg/dl   | 2.41 ± 0.14           | 2.40 ± 0.14                | 2.41 ± 0.14        | 0.586    |
| Phosphorus, mg/dl| 1.13 ± 0.16           | 1.12 ± 0.14                | 1.13 ± 0.15        | 0.647    |
| Total cholesterol, mg/dl | 4.69 ± 0.98 | 4.86 ± 0.91              | 4.79 ± 0.94        | 0.068    |
| Triglyceride, mg/dl | 2.00 ± 1.45      | 2.04 ± 1.35                | 2.02 ± 1.39        | 0.440    |
| HDL-C, mg/dl     | 1.07 ± 0.25           | 1.15 ± 0.31                | 1.11 ± 0.29        | 0.030    |
| LDL-C, mg/dl     | 2.60 ± 0.80           | 2.67 ± 0.77                | 2.64 ± 0.78        | 0.336    |
| BUN, mg/dl       | 5.35 ± 1.09           | 5.22 ± 1.16                | 5.27 ± 1.13        | 0.198    |
| Creatinine, mg/dl| 72.06 ± 10.63         | 74.85 ± 14.26              | 5.27 ± 1.33        | 0.085    |
| CRP, mg/l        | 4.08 ± 1.55           | 3.93 ± 1.71                | 3.99 ± 3.82        | 0.041    |

SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; FPG: fasting plasma glucose; PBG: postprandial blood glucose; HDL-cholesterol: high-density lipoprotein cholesterol; LDL-cholesterol: low-density lipoprotein cholesterol; BUN: blood urea nitrogen; CRP: C-reaction protein.

Table 2: The comparisons of hypertension, T2DM, and smokers in AS and control group.

| Items          | AS group | Control group | Total | P value |
|----------------|----------|---------------|-------|---------|
| Hypertension   | 51 (37.5%)| 65 (32.7%)    | 116 (34.6%) | 0.361   |
| Type 2 DM      | 25 (18.4%)| 25 (12.6%)   | 50 (14.9%)   | 0.190   |
| Smokers        | 57 (41.9%)| 69 (34.7%)   | 126 (37.6%)  | 0.179   |

DM: diabetes mellitus

Table 3: Correlations of OCN with various clinical and biochemical markers in whole study population.

| Markers       | r       | p   |
|---------------|---------|-----|
| SBP           | -0.056  | 0.303|
| DBP           | -0.088  | 0.109|
| BMI           | -0.085  | 0.122|
| Waistline     | -0.090  | 0.102|
| FPG           | -0.311  | <0.001|
| PBG           | -0.272  | <0.001|
| FINS          | -0.091  | 0.096|
| Cr            | 0.125   | 0.022|
| TG            | -0.061  | 0.267|
| TC            | 0.026   | 0.630|
| HDL-C         | 0.074   | 0.176|
| LDL-C         | 0.140   | 0.010|
| CRP           | -0.107  | 0.049|
| HbA1c         | -0.266  | <0.001|

OCN and HbA1c (r = -0.306, p < 0.001), and OCN and PBG (r = -0.365, p < 0.001). In control group, Spearman’s correlation analysis demonstrated a negative correlation between OCN and FPG (r = -0.192, p = 0.007), OCN and HbA1c (r = -0.199, p = 0.005), OCN and PBG (r = -0.147, p = 0.039), and OCN and FINS (r = -0.143, p = 0.043). Moreover, the association between OCN and other risk factors such as age, BMI, SBP, DBP, HbA1c, creatinine, and total cholesterol was also investigated. In AS group, Spearman’s correlation analysis demonstrated a significant correlation between OCN and age (r = 0.186, p = 0.030) and OCN and SBP (r = -0.156, p = 0.070). However, in control group, Spearman’s correlation analysis demonstrated no significant correlation between OCN and other risk factors. On the other hand, as shown in Table 3, in whole study population, OCN was found to have significant positive correlation with creatinine and LDL-C, and negative correlation with FPG, PBG, CRP, and HbA1c (Figure 1).

A logistic regression analysis was conducted to identify the independent association between levels of OCN, traditional atherosclerotic risk factors as well as glucose metabolic markers (including age, BMI, DM, hypertension, SBP, DBP, HbA1c, total cholesterol, creatinine, FPG, PBG, and FINS), and carotid atherosclerosis, and odds ratios.
Figure 1: The correlation between OCN and FPG, PBG, Cr, CRP, LDL-C, and HbA1c.

3.3. Comparisons between the AS Patients and Non-AS Patients among Hypertension Subgroups and T2DM Subgroups. Since hypertension and T2DM were reported to be closely associated with the atherosclerosis, comparisons between the patients with AS or not among such two diseases subgroups were conducted.

Among the hypertension patients (n=116), the DBP of the AS patients (n=51) was significantly higher than that of non-AS patients (n=65) (83.45 ± 10.83 versus 82.31 ± 8.73, p=0.035), but the difference was very small. Interestingly, the FINS of the AS patients was significantly lower than that of non-AS patients (5.70 ± 1.48 versus 5.19 ± 0.84, p<0.001). The FBG of the AS patients was also significantly higher than that of non-AS patients (7.07 ± 3.10 versus 6.59 ± 1.97, p=0.016). The HbA1c of the AS patients was also significantly higher than that of non-AS patients (5.83 ± 0.86 versus 5.56 ± 0.55, p=0.002).

Among the patients with T2DM (n=50), the OCN of the AS patients (n=25) was significantly lower than that of non-AS patients (n=25) (14.13 ± 18.37 versus 18.36 ± 8.70, p=0.028). Interestingly, the total cholesterol of the AS patients was significantly lower than that of non-AS patients (4.64 ± 1.21 versus 4.73 ± 0.84, p=0.047). On the contrary, among the patients without T2DM (n=285), the FPG of the AS patients (n=111) was significantly higher than that of non-AS patients (n=134) (5.33 ± 0.84 versus 5.11 ± 0.70, p=0.030). The FINS of the AS patients was significantly lower than that of non-AS patients (10.05 ± 5.28 versus 10.98 ± 6.64, p=0.030).

4. Discussion

In the present study, we assessed OCN levels in 335 patients including 136 cases with carotid atherosclerosis cases and 199 control cases. Our study revealed that decreased OCN had a close relationship with the carotid atherosclerosis among middle-aged male patients.

In recent years, an increasing number of studies revealed that bones did not only act as a structural support, but also as an important endocrine organ. As an osteoblast-secreted small peptide, OCN was able to bind to hydroxyapatite in bone constitution and was also reported to be the active form of glucose and fat metabolism. For example, a lower level of OCN was found to decrease the glucose tolerance [17], which was consistent with our findings that OCN had negative significant Spearman correlation with HbA1c (r = -0.306, p<0.001). Similarly, this was reflected by the finding that, among the T2DM patients, the OCN of AS patients was significantly lower than that of non-AS patients. The mechanism by which OCN could regulate the glucose metabolism remained to be totally clarified. On one hand, it may be related to the fact that OCN could retard vascular endothelial cells apoptosis through this insulin-sensitizing effect [18], by stimulating the phosphatidylinositol 3-kinase (PI3-kinase)/Akt signaling pathway [19]. On the other hand, OCN could improve insulin resistance by decreasing inflammation and promote insulin signaling as well as the expression of Slc2a4/GLUT4 [20].

Not only was OCN found to be closely related to the glucose metabolism, but such influence was always accompanied with atherosclerotic changes. Abnormal expression of OCN was found to be related to both carotid atherosclerosis and diabetes metabolism. In our study, although there was no significant difference between the number of persons...
with type 2 DM in AS group and control group, the FPG and HbAlc were significantly different in two groups (p=0.004 and p=0.008, respectively). Moreover, Pennisi et al. [21] previously found that the decline of OCN was closely related to the carotid lesion in patients compared with healthy group, with half of the subjects having diabetes. In another Chinese study, OCN was independently associated with carotid atherosclerosis in patients who had impaired glucose regulation [22]. Such phenomenon might be explained by the fact that the early stage of atherosclerosis development is characterized by the endothelial apoptosis and subsequent endothelial dysfunction [23], and endothelial function could be impaired by high plasma concentration of free fatty acid (FFA) [24]. The vascular endothelium sharing the same pathway involves the insulin metastasis [18]. Therefore, through the aforementioned PI3-kinase dependent manner, OCN could promote the phosphorylation of endothelial cells’ secretions and prevent its insulin-stimulated changes, thus decreasing the FFA-induced apoptosis of vascular endothelial cells [18].

The incidence of the carotid atherosclerosis is associated with elevation of blood pressure, and each 20-mmHg in SBP or 10-mmHg DBP was associated with more than twofold increased risk of cardiovascular death, including carotid atherosclerotic events [25]. Since hypertension is strongly associated with endothelial function, whose dysfunction could lead to abnormal expression of vasoactive substances and induce dysfunctional contraction or dilation of blood vessels, it is suspected that there could be a potential relationship between OCN and SBP/DBP. In our study, we found no significant correlation between SBP/DBP and OCN, and there is no significant difference between the number of hypertension patients in AS group and control group. Such finding was similar to the previous human study conducted by Xu et. al. [26], but was inconsistent with their mice study which indicated that exogenous OCN significantly reduced the mean blood pressure level and promoted vascular endothelium-dependent relaxation of the aortic arch [27]. It is not clarified how OCN influences the blood pressure in human and thus more investigations are needed.

In our study, CRP and HDL-C were found to be significantly different in AS group and control group, and CRP was also found to be independently and inversely related to OCN. This was similar to the findings by Lombardo et. at. [28] that elevated CRP might indicate carotid plaque instability, and predict the presence of atherosclerosis [3]. However, despite the fact that OCN might be the potential link between carotid atherosclerosis and inflammation (CRP), the mechanism by which OCN reflects the changes of CRP in the atherosclerotic pathology remains to be unknown, and future investigations are needed to make it clarified.

Our study has some limitations. First, we did not differentiate OCN into carboxylated OCN (cOCN) and uncacbokylated OCN (unOCN) and make comparisons between them. cOCN was reported to be decarboxylated in the acidic environment during active bone resorption and released into circulation [29], while unOCN could not be secreted into circulation due to its reduced binding affinity for bone minerals in vitamin K environment [30]. However, some clinical studies indicated that both cOCN and unOCN were associated with energy metabolism and atherosclerosis [31]. For example, Ogawa-Furuya et. al reported that the ucOCN levels were inversely related to the abdominal aortic calcification score in men [32]. On the other hand, others reported that vitamin K could accelerate the transference of uncarboxylated osteocalcin to carboxylated osteocalcin [33], and thus the ratio of such two types of osteocalcin could be influenced and reflected by the current diet vitamin K intake [34]. Second, we did not include the individual thickness of CIMT in each patient or stratify its thickness to investigate the potential relationship between its thickness and OCN level and other parameters. Luo and his colleagues found that the age, SBP, FPG, FINS, and CRP were independently associated with C-IMT in a metabolically healthy Chinese population [35]. Finally, since our study is a cross-sectional study, it is not clear whether the abnormal expression of OCN is the causal factor of carotid atherosclerosis. Therefore, more prospective studies are necessary to address such issue.

In summary, we confirmed that the serum OCN level was inversely associated with the carotid atherosclerosis in middle-aged male adults. Due to the significant correlation between OCN and FPG, PBG, and HbAlc, the effects of OCN on atherosclerosis might be closely related to its ability to improve glucose and lipid metabolism.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] V. L. Roger, A. S Go, D. M. Lloyd-Jones, R. J. Adams et al., “Heart disease and stroke statistics—2011 update: A report from the American Heart Association,” Circulation, vol. 129, pp. e28–e92, 2013.
[2] A. J. Grau, C. Weimar, F. Buggle et al., “Risk factors, outcome, and treatment in subtypes of ischemic stroke: The German stroke data bank,” Stroke, vol. 32, no. 11, pp. 2559–2566, 2001.
[3] F. Jashari, P. Ibrahim, R. Nicoll, G. Bajraktari, P. Wester, and M. Y. Henein, “Coronary and carotid atherosclerosis: similarities and differences,” Atherosclerosis, vol. 227, no. 2, pp. 193–200, 2013.
[4] M.-J. Van Rooy and E. Pretorius, “Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events,” Current medicinal chemistry, vol. 21, no. 19, pp. 2121–2129, 2014.
[5] A. Melidonis, I. A. Kyriazis, A. Georgopali et al., “Prognostic value of the carotid artery intima-media thickness for the presence and severity of coronary artery disease in type 2 diabetic patients,” Diabetes care, vol. 26, no. 11, pp. 3189-3190, 2003.
[6] E. de Groot, S. I. van Leuven, R. Duivenvoorden et al., “Measurement of carotid intima-media thickness to assess
progression and regression of atherosclerosis,” *Nature Clinical Practice Cardiovascular Medicine*, vol. 5, no. 5, pp. 280–288, 2008.

[7] H. Sumino, S. Ichikawa, S. Kasama et al., “Relationship between carotid atherosclerosis and lumbar spine bone mineral density in postmenopausal women,” *Hypertension Research*, vol. 31, no. 6, pp. 191–197, 2008.

[8] L. C. Holbauer, C. C. Brueck, C. M. Shanahan, M. Schoppet, and H. Dobnig, “Vascular calcification and osteoporosis - From clinical observation towards molecular understanding,” *Osteoporosis International*, vol. 18, no. 3, pp. 251–259, 2007.

[9] R. Okabe, M. Inaba, K. Nakatsuka et al., “Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxyypyridinoline,” *Journal of Bone and Mineral Metabolism*, vol. 22, no. 2, pp. 127–131, 2004.

[10] N. K. Lee, H. Sowa, E. Hinoi et al., “Endocrine regulation of energy metabolism by the skeleton,” *Cell*, vol. 130, no. 3, pp. 456–469, 2007.

[11] P. Duyck, M. Amling, S. Takeda et al., “Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass,” *Cell*, vol. 100, no. 2, pp. 197–207, 2000.

[12] L. Chen, Q. Li, Z. Yang et al., “Osteocalcin, glucose metabolism, lipid profile and chronic low-grade inflammation in middle-aged and elderly Chinese,” *Diabetic Medicine*, vol. 30, no. 3, pp. 309–317, 2013.

[13] Y. Bao, M. Zhou, Z. Lu et al., “Serum levels of osteocalcin are inversely associated with the metabolic syndrome and the severity of coronary artery disease in Chinese men,” *Clinical Endocrinology*, vol. 75, no. 2, pp. 196–201, 2011.

[14] R. Cifkova, S. Erdine, R. Fagard et al., “Practice Guidelines for Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines,” *Journal of Hypertension*, vol. 21, no. 10, pp. 1779–1876, 2003.

[15] J. P. Brown and R. G. Josse, “Scientific Advisory Council of the Osteoporosis Society of Canada,” pp. SI-S34, 2002.

[16] M. Żabczyk, Ł. Hońdo, M. Krzek, and A. Undas, “High-density cholesterol and apolipoprotein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals,” *Blood Coagulation & Fibrinolysis*, vol. 24, no. 1, pp. 50–54, 2013.

[17] B. B. Yeap, H. Alfonso, S. A. Paul Chubb et al., “Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 100, no. 1, pp. 63–71, 2015.

[18] C. H. Jung, W. J. Lee, J. Y. Hwang et al., “The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway,” *Metabolism - Clinical and Experimental*, vol. 62, no. 9, pp. 1250–1257, 2013.

[19] M. Ferron, M. D. McKee, R. L. Levine, P. Duyck, and G. Karsenty, “Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice,” *Bone*, vol. 50, no. 2, pp. 568–573, 2012.

[20] J. A. C. Guedes, J. V. Esteves, M. R. Morais, T. M. Zorn, and D. T. Furuya, “Osteocalcin improves insulin resistance and inflammation in obese mice: Participation of white adipose tissue and bone,” *Bone*, 2017.

[21] P. Pennisi, S. S. Signorelli, S. Riccobene et al., “Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels,” *Osteoporosis International*, vol. 15, no. 5, pp. 389–395, 2004.

[22] H. Ma, H. Lin, Y. Hu et al., “Serum levels of osteocalcin in relation to glucose metabolism and carotid atherosclerosis in Chinese middle-aged and elderly male adults: The Shanghai Changfeng Study,” *European Journal of Internal Medicine*, vol. 25, no. 3, pp. 259–264, 2014.

[23] J. C. Choy, D. J. Granville, D. W. C. Hunt, and B. M. McManus, “Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis,” *Journal of Molecular and Cellular Cardiology*, vol. 33, no. 9, pp. 1673–1690, 2001.

[24] Y. Azekoshi, T. Yasu, S. Watanabe et al., “Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells,” *Hypertension*, vol. 56, no. 1, pp. 136–142, 2010.

[25] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, “Age-specific relevance of usual blood pressure to vascular mortality,” *The Lancet*, vol. 361, no. 9366, pp. 1391-1392, 2003.

[26] Y. Xu, X. Ma, Q. Xiong et al., “Association between serum osteocalcin level and blood pressure in a Chinese population,” *Blood Pressure*, vol. 27, no. 2, pp. 106–111, 2018.

[27] J. Dou, H. Li, X. Ma et al., “Osteocalcin attenuates high fat diet-induced impairment of endothelium-dependent relaxation through Akt/eNOS-dependent pathway,” *Cardiovascular Diabetes*, vol. 13, no. 1, article 74, 2014.

[28] A. Lombardo, L. M. Biasucci, G. A. Lanza et al., “Inflammation as a possible link between coronary and carotid plaque instability,” *Circulation*, vol. 109, no. 25, pp. 3158–3163, 2004.

[29] M. Ferron, J. Wei, T. Yoshizawa et al., “Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism,” *Cell*, vol. 142, no. 2, pp. 296–308, 2010.

[30] M. F. Faienza, V. Luce, A. Ventura et al., “Osteocalcin and glucose metabolism: A bone-pancreas loop,” *International Journal of Endocrinology*, vol. 2015, 7 pages, 2015.

[31] R. Reyes-Garcia, P. Rozas-moreno, J. J. Jimenez-moleon et al., “Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes,” *Diabetes & Metabolism*, vol. 38, no. 1, pp. 76–81, 2012.

[32] N. Ogawa-Furuya, T. Yamaguchi, M. Yamamoto, I. Kanazawa, and T. Sugimoto, “Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus,” *Osteoporosis International*, vol. 24, no. 8, pp. 2223–2230, 2013.

[33] S. L. Booth, A. Centi, S. R. Smith, and C. Gundberg, “The role of osteocalcin in human glucose metabolism: marker or mediator?” *Nature Reviews Endocrinology*, vol. 9, no. 1, pp. 43–55, 2013.

[34] S. L. Booth and A. A. Rajabi, “Determinants of vitamin K status in humans,” *Vitamins & Hormones*, vol. 78, pp. 1–22, 2008.

[35] Y. Luo, X. Ma, Y. Hao et al., “Relationship between serum osteocalcin level and carotid intima-media thickness in a metabolically healthy Chinese population,” *Cardiovascular Diabetes*, vol. 14, no. 1, p. 82, 2015.